Imquest Biosciences

UEI: Y7ETNZCNSLM5 • CAGE: 3Y2E4

Overview

Awardee Type

Parent

Federal Capability Statement

ImQuest BioSciences provides preclinical contract research and development services to help pharmaceutical and biotechnology companies successfully bring new pharmaceuticals and biologics to market. ImQuest BioSciences offers non-GLP and GLP compliant services to define the efficacy, safety, and pharmaceutical property of drug candidates and potential new biologics from initial discovery and screening to IND-enabling studies. ImQuest Biosciences provides expert professional and technical services. Our technical services include, flow cytometry, immunoassay development, molecular biology, tissue culture, virus production, enzymology, and analytical services to facilitate and streamline your laboratory operations and discovery initiatives.

Keywords

Preclinical contract research, development services, pharmaceutical and biotechnology companies, antiviral product development services, antimicrobial product development services, antimicrobial prevention product development, women's health product development, in vitro/ex vivo toxicology services, pharmaceutical product characterization services, anticancer product development services

Website

http://imquestbio.com

Headquarters

Frederick, MD
United States

Most Recent Award

Sept. 3, 2024

Calculating

Federal contract and grant recipient IMQUEST BIOSCIENCES, INC. dba IMQUEST BIOSCIENCES INC (UEI Y7ETNZCNSLM5, CAGE 3Y2E4) is headquartered in Frederick MD. Its primary registered NAICS is 541714 Research and Development in Biotechnology (except Nanobiotechnology). The corporation was founded in March 2004 and federally registered in July 2004.

Federal Award Analysis